<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01322932</url>
  </required_header>
  <id_info>
    <org_study_id>151/10</org_study_id>
    <nct_id>NCT01322932</nct_id>
  </id_info>
  <brief_title>Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey</brief_title>
  <official_title>HIV-positive Patients Under Tenofovir, Emtricitabine and Efavirenz Therapy Switching From a Two-pill Regimen to a Single Pill Regimen: Patients'Opinion Survey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Policlinique Médicale Universitaire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss HIV Cohort Study</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Policlinique Médicale Universitaire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess adherence, tolerability and satisfaction of each
      eligible HIV subjects switching from a two- or three-pill tenofovir-emtricitabine-efavirenz
      (TDF-FTC-EFV) to a one-pill TDF-FTC-EFV treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each eligible patient will be screened from de SHCS database. Each refusal and drop-out will
      be documented. A pre-visit (V-1) will be scheduled for informed consent, V0 for inclusion
      (V-1 and V0 may occur on the same day), V1 one month post-inclusion and V2 4 to 7 months
      post-inclusion. V0, V1 and V2 will be planned during regular medical visits.

      Eligible patients either get their cART in their usual pharmacy according to standard of
      care, or take part in a routine adherence-enhancing program(adherence subgroup)run by the
      pharmacists of the outpatient medical clinic.

      In the adherence subgroup, adherence is assessed electronically by MEMS (Medication event
      monitoring system) monitors on a regular basis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient adherence</measure>
    <time_frame>V0, V1, V2</time_frame>
    <description>by questionnaire in both subgroups and by MEMS data in the adherence subgroup</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events and symptoms</measure>
    <time_frame>V0, V1, V2</time_frame>
    <description>by questionnaires</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment management</measure>
    <time_frame>V0, V1, V2</time_frame>
    <description>Treatment management according to meals, timing, disruptive daily schedule By questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction of the switch</measure>
    <time_frame>V1, V2</time_frame>
    <description>By questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of switch on clinical outcomes</measure>
    <time_frame>V0, V1, V2</time_frame>
    <description>Clincal outcomes = viral load, CD4 count, resistance, EFV blood level. By medical file</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' acceptance of switch</measure>
    <time_frame>V-1</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">95</enrollment>
  <condition>HIV Infection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients under TDF-FTC-EFV followed up at the Service of Infectious Disease of the
        University Hospital of Lausanne and enrolled in the Swiss HIV Cohort Study (SHCS) Adherence
        subgroup: patients enrolled in the HIV adherence program at the pharmacy of the Department
        of Ambulatory Care &amp; Community Medicine in Lausanne.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients under TDF-FTC-EFV

          -  followed up at the Service of Infectious Disease of the University Hospital of
             Lausanne

          -  enrolled in the SHCS

        Exclusion Criteria:

          -  patients receiving TDF-FTC-EFV in combination with other ARTs

          -  patients under TDF-FTC-EFV for less than 3 months

          -  patients not fluent in French
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Cavassini, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Paule Schneider, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinique Médicale Universitaire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier Bugnon, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Policlinique Médicale Universitaire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aurélie Gertsch, PhD Student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinique Médicale Universitaire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois et Policlinique Medicale Universitaire</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2011</study_first_submitted>
  <study_first_submitted_qc>March 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2011</study_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Policlinique Médicale Universitaire</investigator_affiliation>
    <investigator_full_name>Marie Schneider</investigator_full_name>
    <investigator_title>Pharmacist, PhD</investigator_title>
  </responsible_party>
  <keyword>Medication Adherence</keyword>
  <keyword>HIV Infection</keyword>
  <keyword>efavirenz, emtricitabine, tenofovir disoproxil fumarate drug combination [Substance Name]</keyword>
  <keyword>efavirenz</keyword>
  <keyword>emtricitabine</keyword>
  <keyword>Patient Satisfaction</keyword>
  <keyword>tenofovir disoproxil fumarate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

